Because the enzymatic modification of heparan sulfate proteoglycans can dramatically modify tumor cell behavior [53], our data suggest that the heparan sulfate proteoglycan biosynthetic process is a potential therapeutic target for patients with OSCC who have the CNA in this pathway. The gene discussed is CD44; the disease is neoplasm.